Overview

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Status:
Terminated
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan